You are here: Industry Insights > Regeneron

News List

Regeneron and Intellia to develop new haemophilia therapies pharmaceutical-technology
June 03, 2020
Regeneron Pharmaceuticals has expanded its ongoing partnership with Intellia Therapeutics for the development of therapies for haemophilia A and B.
Regeneron, Intellia Expand CRISPR/Cas9 Alliance contractpharma
June 02, 2020
Provides Regeneron with rights to develop additional CRISPR/Cas9-based therapeutic targets and to jointly develop potential products for hemophilia A and B.
Dupixent Eosinophilic Esophagitis Trial Meets Both Co-Primary Endpoints americanpharmaceuticalreview
June 01, 2020
Regeneron Pharmaceuticals and Sanofi announced positive results from Part A of the pivotal Phase 3 trial evaluating Dupixent® (dupilumab) in patients 12 years and older with eosinophilic esophagitis (EoE).
Sanofi intends to sell its equity investment in Regeneron; confirms no change to ongoing collaborati worldpharmanews
May 28, 2020
Sanofi announced its intent to sell its equity investment in Regeneron through a registered public offering and related share repurchase by Regeneron.
Sanofi to sell stake in Regeneron pharmatimes
May 27, 2020
Sanofi has revealed its intent to sell its equity investment in Regeneron through a registered public offering and related share repurchase by the firm.
Regeneron, CCPM Enter Genetics Research Alliance contractpharma
May 12, 2020
Large-scale genomics initiative aims to advance human genetics and precision medicine.
Sanofi/Regeneron's Libtayo shows benefit in BCC pharmatimes
May 08, 2020
Sanofi and Regeneron's Libtayo (cemiplimab) has demonstrated 'clinically meaningful and durable responses' in a subset of patients with basal call carcinoma (BCC) from whom there are currently no approved treatments.
Regeneron says COVID-19 antibody cocktail may be available by fall expresspharma
May 06, 2020
The company is one of the many drugmakers looking to tackle COVID-19, caused by the new coronavirus that has no current approved treatment or vaccine and has claimed over 250,000 lives worldwide.
Phase III Lung Cancer Trial Stopped Early Due to Significant Survival Improvement americanpharmaceuticalreview
April 29, 2020
Regeneron and Sanofi announced the primary endpoint of overall survival (OS) was met in a Phase 3 trial comparing the PD-1 inhibitor Libtayo® (cemiplimab).
Regeneron, Sanofi Release Preliminary Phase II Kevzara Results in COVID-19 contractpharma
April 28, 2020
Kevzara rapidly lowered C-reactive protein (CRP), a key marker of inflammation, meeting the primary endpoint.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page